Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-09-11T02:44:41.735Z.
Calculation as of: 2026-09-11T02:44:41.735Z.
Quote observation: 2026-09-10T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d670d92a9ed985c4ba88d5830250f1e4eb43691fb1e0723b4e8904464d1c2daf
PE RATIO
N/A
Market Cap
$10.46B
PE Ratio
7.08
TTM Avg
8.78
3Y Avg
12.12
5Y Avg
12.16
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $10.29B | N/A | N/A | N/A | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.45B | 1054.11 | 162.23 | 65.70 | 49.23 |
| Universal Health Services, Inc. (UHS)vs › | $10.46B | 7.08 | 8.78 | 12.12 | 12.16 |
| The Ensign Group, Inc. (ENSG)vs › | $10.07B | 27.08 | 30.98 | 30.47 | 27.64 |
| The Cooper Companies, Inc. (COO)vs › | $10.56B | 18.49 | 43.06 | 49.50 | 34.05 |
| Henry Schein, Inc. (HSIC)vs › | $9.94B | 25.45 | 23.70 | 23.83 | 21.80 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 44.70 | 31.88 | 30.89 | 19.14 |
| Globus Medical, Inc. (GMED)vs › | $9.92B | 18.91 | 23.35 | 68.14 | 56.94 |
| Align Technology, Inc. (ALGN)vs › | $10.79B | 26.17 | 29.05 | 38.16 | 44.36 |
| Insulet Corp. (PODD)vs › | $9.33B | 25.17 | 64.24 | 69.03 | 3650.62 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$58.74
Forward EPS (Est.)
$-0.20
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
